Ultragenyx Pharmaceutical (RARE) EBIT Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 32.96% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -29.67% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -50.81% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.47% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.35% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -12.10% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 55.96% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -3.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.12% |
| Dec 31, 2025 | 8.03% |
| Sep 30, 2025 | 8.77% |
| Jun 30, 2025 | 8.66% |
| Mar 31, 2025 | -1.53% |
| Dec 31, 2024 | -6.04% |
| Sep 30, 2024 | -13.69% |
| Jun 30, 2024 | -12.02% |
| Mar 31, 2024 | -15.77% |
| Dec 31, 2023 | -8.24% |
| Sep 30, 2023 | -42.34% |
| Jun 30, 2023 | -32.88% |
| Mar 31, 2023 | -8.50% |
| Dec 31, 2022 | -15.53% |
| Sep 30, 2022 | -24.00% |
| Jun 30, 2022 | -7.98% |
| Mar 31, 2022 | -11.26% |
| Dec 31, 2021 | -4.32% |
| Sep 30, 2021 | -0.07% |
| Jun 30, 2021 | 4.45% |
| Mar 31, 2021 | -3.37% |
| Dec 31, 2020 | 0.26% |
| Sep 30, 2020 | 15.61% |
| Jun 30, 2020 | 7.02% |
| Mar 31, 2020 | -19.93% |
| Dec 31, 2019 | -10.21% |
| Sep 30, 2019 | -21.52% |
| Jun 30, 2019 | -24.66% |
| Mar 31, 2019 | -22.77% |
| Dec 31, 2018 | -17.17% |
| Sep 30, 2018 | -30.93% |
| Jun 30, 2018 | -46.57% |
| Mar 31, 2018 | -64.94% |
| Dec 31, 2017 | -78.79% |
| Sep 30, 2017 | -74.20% |
| Jun 30, 2017 | -79.07% |
| Mar 31, 2017 | -89.14% |
| Dec 31, 2016 | -94.93% |
| Sep 30, 2016 | -103.89% |
| Jun 30, 2016 | -91.65% |
| Mar 31, 2016 | -99.56% |